Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Regulated endocrine-specific protein 18 (RESP18) is a luminal protein localized mainly to the dense core vesicles of pancreatic islet cells and neuroendocrine tissues, where it participates in secretory processes such as granule cargo packing and regulated secretion[1][3][4][6]. Its expression is induced by high glucose and is genetically linked with other dense core vesicle proteins (e.g., IA-2)[1][6]. RESP18 shows differential expression in response to neurotoxic stress and may contribute to ER stress and neuronal cell death in specific models[1]. Mutations in the RESP18 gene have been implicated in hereditary non-syndromic cleft lip and palate, suggesting a critical developmental role[2]. While RESP18 is biologically relevant, it is not currently considered a mainstream therapeutic target, and no drugs are known to target it directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Regulated endocrine-specific protein 18 (RESP18).